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Introduction
Lung cancer is the most common malignant disease and the leading cause of cancer-related death worldwide. 1 With the development of novel antitumor agents, including targeted and anti-emetic drugs of low toxicities, more and more patients at advanced stage can maintain good performance status in order to continue subsequent treatment after completing standard first and second-line treatments. However, there are few recommendations for third-line chemotherapy or beyond for these patients and palliative care remains the standard approach. Chemotherapy drugs that can present good, well-tolerated clinical outcomes in patients who have failed multi-line therapy are urgently required. Paclitaxel is one of the most widely used and effective antitumor agents derived from natural sources and plays an important role in non-small-cell lung cancer (NSCLC). [2] [3] [4] Traditional solvent-based paclitaxel is associated with hypersensitivity reactions to the polyoxyethylated castor oil in which it is dissolving. Therefore, pretreatment with a large quantity of drugs, such as corticosteroids and antihistamines, is required. As is universally known, many patients with lung cancer have a series of comorbidities, such as hypertension and diabetes, which limit the use of high dose steroids. Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an albumin-bound formulation of paclitaxel and allows the administration of paclitaxel without the use of lipid-based solvents, which reduces the risk of hypersensitive reactions, and can therefore be administered without the need for corticosteroid and antihistamine premedication. 5, 6 Furthermore, albumin has the potential to increase drug delivery to tumors. 7, 8 Equitoxic doses of NAB-paclitaxel have been much higher than those of traditional paclitaxel in both preclinical and clinical studies.
9,10 NAB-paclitaxel has been studied as a first-line therapy and has achieved convincing antitumor activity in advanced NSCLC patients. 11, 12 However, compared with the standard firstline regimen of paclitaxel in combination with platinum, NAB-paclitaxel alone did not present a better clinical outcome. As a first-line therapeutic strategy, NAB-paclitaxel failed to demonstrate any advantage beyond previous standard chemotherapy and is less cost-effective than traditional paclitaxel. 13 However, there is currently limited evidence to indicate that NAB-paclitaxel may be a subsequent choice for advanced NSCLC patients who have failed multi-lines of chemotherapy and targeted therapy. 14 Notably, albumin has the natural ability to promote drug delivery to tumors by initiating albumin receptor (gp60)-mediated transcytosis across endothelial cells, accumulating the drug in tumors by binding to secreted protein acidic and rich in cysteine (SPARC), a well-known matricellular molecule involved in multiple processes in various cancers. 7, 9 SPARC may help to facilitate metastasis by increasing the migration and invasion capacity of prostate and breast cells in vitro. 15, 16 Several studies have shown that SPARC overexpression is associated with poor prognosis. [17] [18] [19] [20] lesions, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR = CR + PR), and disease control rate (DCR = CR + PR + SD). Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. Progression-free survival (PFS) was defined as the time from the first administration of NAB-paclitaxel to the first objective progression of disease. Overall survival (OS) was defined as the time from the first administration of NABpaclitaxel to death or loss of follow-up. If the patient remained alive at the last follow-up, the data was treated as censored. The authors had access to identifying information during and after data collection.
Immunohistochemistry
Immunohistochemistry (IHC) was used to demonstrate the presence and location of SPARC in tumor tissue samples. Briefly, dried five-micron slides with formalin-fixed and paraffin-embedded tissue were prepared. Antigens were retrieved using ethylene-diamine-tetraacetic acid buffer and incubation at 100 C for 15 minutes. Slides were then incubated overnight at 4 C with monoclonal mouse antiosteonectin/SPARC antibody (Invitrogen, Carlsbad, CA, USA) at 7 μg/mL. A two-step polymer-horseradish peroxidase method (GTVision, Beijing, China) was used for detection and 3,3 0 -diaminobenzidine-tetrahydrochloride staining. No staining was observed for the negative control, which was incubated with phosphate buffered saline instead of monoclonal mouse anti-osteonectin/SPARC antibody. Positive IHC was defined if more than 10% of cancer or tumor stroma cells were stained. Two different pathologists independently evaluated the results of IHC staining.
Statistical methods
All data were summarized descriptively, and two-sided 95% CIs were presented. PFS and OS were summarized using Kaplan-Meier methods. The indexes affecting PFS and OS were analyzed using the Cox regression model.
Results
The baseline characteristics of the 62 patients are presented in Table 1 (except the two patients who discontinued chemotherapy as a result of severe adverse events). All patients were categorized as clinical stage IV; 83.9% of patients received NAB-paclitaxel as fourth-line therapy or beyond.
Efficacy
Response evaluation was performed for 62 patients. The ORR for NAB-paclitaxel was 16.1% (10/62) and the DCR (CR + PR + SD) was 64.5% (40/62). Up to 30 November 2016, the median PFS was 3.7 months (95% CI 2.6-4.8) and the median OS was 9.8 months (95% CI 6.9-12.8) (Fig 1) . All nine patients with PR were diagnosed with adenocarcinoma, eight had received previous solvent-based paclitaxel or docetaxel therapy, and eight received NABpaclitaxel as fourth-line or further chemotherapy.
Epidermal growth factor receptor mutation status was detected in 60 patients and 21 (32.3%) cases presented EGFR mutation. No statistically significant differences in PFS and OS after NAB-paclitaxel treatment were observed between EGFR mutated and wild-type patients (P > 0.05). Two of the patient samples were insufficient; therefore the pathology could not be further classified. No correlations were observed between age, gender, pathology, PS status, or previous antitumor therapy and clinical outcome of NAB-paclitaxel (Table 2) . Cox regression analysis showed that response was related with both OS and PFS (Fig 2) .
Pearson's correlation analysis was conducted to further determine whether previous solvent-based paclitaxel or Secreted protein acidic and rich in cysteine expression and its correlation to nanoparticle albumin-bound paclitaxel response
Only 28 of the patients included in the study were able to provide enough tumor tissue to test SPARC expression. We investigated SPARC expression in cancer and tumor stroma cells. In tumor stroma cells, SPARC expression was most clearly observed in the cytoplasm of peritumoral fibroblasts. The extracellular matrix and other local inflammatory cells (macrophages and lymphocytes) did not show SPARC expression. Nine patients (32.1%) were classified as cancer cell negative/tumor stroma cell negative, three (10.7%) as cancer cell positive/tumor stroma cell negative, three (10.7%) as cancer cell negative/tumor stroma cell positive, and 13 patients (46.5%) were classified as cancer cell positive/tumor stroma cell positive (Fig 3) . Because of the limited number of patients, we analyzed the associations of SPARC expression in cancer and tumor stroma cells with response to NAB-paclitaxel (Table 4) . SPARC expression in tumor stroma cells was correlated with response to NAB-paclitaxel, with 5.0 and 3.3 months for SPARC negative and SPARC positive, respectively ( Fig 4) ; P was statistically significant (P = 0.036). However, there was no correlation between SPARC expression in cancer cells and response to NAB-paclitaxel.
Safety
Treatment was well tolerated in most patients receiving NAB-paclitaxel at the full dose (with the exception of two patients). All patients received 0.5-10 cycles (median: four cycles) of NAB-paclitaxel monotherapy, while 10 received only 0.5-1 cycle of NAB-paclitaxel because of worsening symptoms. The most frequent treatment related AEs are presented in Table 5 . The major grade 3-4 toxicities were leukopenia (6/64, 9.4%), neutropenia (5/64, 7.8%), and peripheral neuropathy (2/64, 3.1%). Other NAB-paclitaxel associated toxicities, including gastrointestinal AEs, rash, and anemia were mild to moderate and easily managed. Two patients had to discontinue chemotherapy because of drug induced serious fatigue and serious anorexia, respectively.
Discussion
Along with the development of targeted agents based on driver genes related to lung cancer and low toxicity chemotherapy, NSCLC patient survival, particularly in regard to lung adenocarcinoma, has been greatly improved. Prolongation of survival duration increases the opportunity for patients to receive multi-line treatment. Chemotherapy remains an important strategy, not only for EGFR wildtype patients, but also for patients with EGFR mutations. However, to date, a therapeutic regimen after second or third-line treatment failure is still required. In our study, weekly administration of NAB-paclitaxel displayed convincing therapeutic efficacy in patients who had previously undergone multi-lines of therapy for advanced NSCLC and was well tolerated. More than 80% of the patients in this study received NAB-paclitaxel as fourth-line therapy or beyond, and the ORR and DCR were 16.1% and 64.5%, respectively, with a median PFS of 3.7 months (95% CI 2.6-4.8) and median OS of 9.8 months (95% CI 6.9-12.8). In particular, in the 10 patients who reached PR, eight had received 4-6 previous lines of therapy, including solvent-based paclitaxel or docetaxel, and all were categorized as clinical stage IV at the beginning of NAB-paclitaxel treatment. Similar circumstances occurred in patients who achieved SD. Previous phase III trials for second or third-line therapy of NSCLC patients have reported ORRs of 7.6-9.1%, median PFS of 2.0-2.9 months, and median OS of 6.7-8.3 months. [22] [23] [24] [25] [26] In this study, more than 50% of patients received at least four cycles of NAB-paclitaxel. More than half of the patients had multiple comorbidities, such as hypertension, diabetes, hepatitis B, and heart disease, which inevitably affected functional status, general health, and chemotherapy tolerance. Overall, a weekly dose of 130 mg/m 2 NABpaclitaxel was well tolerated and no treatment-related death occurred. Patients who were not treated with corticosteroids before NAB-paclitaxel experienced no hypersensitivity. In a randomized phase III trial, compared directly with solvent-based paclitaxel plus carboplatin, a weekly dose of 100 mg/m 2 NAB-paclitaxel (on days 1 and 8) plus carboplatin administered every three weeks showed significantly higher response rates and time to progression, with a decreased incidence of grade 4 neutropenia in 1038 untreated patients with stage IIIb-IV NSCLC. 13 However, as anticipated with a higher paclitaxel dose, dose-limiting toxicities included 0.5% grade 3 and 4 peripheral neuropathy in the NAB-paclitaxel group compared with 2.3% in the solvent-based paclitaxel group (P < 0.001). In our study, the major grade 3-4 toxicities were leukopenia (6/64, 9.4%), neutropenia (5/64, 7.8%), and peripheral neuropathy (2/64, 3.1%), which were resolved with appropriate support treatment. Peripheral neuropathy was mild to moderate and was alleviated when NAB-paclitaxel treatment was discontinued. Weekly administration of NABpaclitaxel seems to be an ideal regimen for NSCLC patients, especially when the use of steroids is contraindicated or after multiple lines of treatment.
Because solvent-based paclitaxel or docetaxel is the standard first or second-line therapy regimen, it is necessary to determine whether traditional taxane may influence subsequent NAB-paclitaxel therapy. Our data showed that previous treatment with solvent-based paclitaxel or docetaxel did not affect the response to NAB-paclitaxel. Similar results were observed in several prospective clinical trials, for example, in breast cancer patients who had failed previous taxane treatment received NAB-paclitaxel. 27, 28 As such, we conclude that previous taxane therapy does not affect the response to NAB-paclitaxel, which might be attributed to the different action mechanisms of the two kinds of agents. However, we found that the patients who achieved disease control after solvent-based paclitaxel or docetaxel administration benefitted more from NAB-paclitaxel than patients who did not, although the result did not reach statistical significance. This may be a result of NAB technology, which, when albumin with paclitaxel particles are combined, enables a greater amount of NAB-paclitaxel to enter the tumor tissue, with high intra-tumor drug concentration.
Whether SPARC expression is a predictor for NABpaclitaxel therapy remains controversial. A study by Desal et al. showed that SPARC might be a predictive biomarker of response to NAB-paclitaxel. 29 An opposing result was reported by Schneeweiss et al. in that the efficacy of NABpaclitaxel did not seem to be associated with SPARC expression in metastatic breast cancer, in either tumor tissues or plasma samples. 30 Koukourakis et al. analyzed SPRAC expression in 113 tumor samples from patients with early operable NSCLC. 31 The results showed that stroma SPARC expression was linked with tumor necrosis and SPARC production by stroma cells supported a high degree of vascular maturation. Survival analysis demonstrated a significant association between stroma SPARC and poor prognosis (P = 0.006). However, the authors did not collect treatment data for these patients after disease relapse or progression and, thus, could not evaluate the relationship between stroma SPARC expression and response to NAB-paclitaxel. Our study showed that SPARC expression in tumor stroma cells, but not in cancer cells, was correlated with response to NAB-paclitaxel. To the best of our knowledge, this is the first time the relationship between SPARC expression in tumor stroma or cancer cells and response to NAB-paclitaxel has been investigated. However, because of the limited number of patients and the retrospective feature of this study, the predictive role of SPARC expression in tumor stroma cells to NAB-paclitaxel needs to be verified by a large sample study.
There were some limitations to our study. First, this is a retrospective study and all of the patients received NABpaclitaxel as third-line or further treatment. In the real world, few patients accept subsequent biopsies during their disease course because of multiple reasons, including personal wishes or the difficult location of a nodule for needle biopsy. Therefore, we could only evaluate SPARC expression in the tumor samples available, and these were not real time subsequent biopsies performed before NABpaclitaxel administration. Second, the number of enrolled patients was limited, which may lead to selection bias. Because of the expense of NAB-paclitaxel and the fact that it is not covered by medical insurance, this treatment is limited to those that can afford it. These factors indicate that we must evaluate the results of our study with caution.
In conclusion, NAB-paclitaxel displays convincing antitumor activity for the management of advanced NSCLC, even in patients who have received multiple lines of treatment. With a high therapeutic index and low side effects, weekly NAB-paclitaxel administration seems to have the ideal clinical benefit-risk ratio. A large-scale, prospective, randomized clinical study is required to provide supportive data for this regimen.
